Comparative Pharmacology
Head-to-head clinical analysis: A P L versus ANDEMBRY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: A P L versus ANDEMBRY.
A.P.L. vs ANDEMBRY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
A.P.L. (Chorionic Gonadotropin) acts as a luteinizing hormone (LH) agonist, binding to LH receptors in the gonads to stimulate testosterone production in males and ovulation in females.
Binds to androgens, progesterone, and estradiol, inhibiting their effects on hormone-responsive tissues; also binds to microtubules and inhibits tubulin polymerization.
500-1000 mg every 4-6 hours, not to exceed 3000 mg/day in adults.
ANDEMBRY (capivasertib) 400 mg orally twice daily, taken with or without food, in combination with fulvestrant. Continue until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal elimination half-life: 2.5–3.5 hours (elimination phase); clinical context: requires repeated dosing for sustained effect.
Terminal elimination half-life is 12-15 hours in healthy adults; may be prolonged up to 20-25 hours in patients with moderate to severe hepatic impairment.
Renal: 10% unchanged; hepatic metabolism to inactive metabolites excreted in urine and feces (90% combined).
Primarily renal excretion of unchanged drug (approximately 70-80%) and as metabolites (10-15%); biliary/fecal elimination accounts for less than 10%.
Category C
Category C
Gonadotropin
Gonadotropin